Edition:
United States

ALK-Abello A/S (ALKb.CO)

ALKb.CO on Copenhagen Stock Exchange

986.00DKK
25 Sep 2017
Change (% chg)

-- (--)
Prev Close
kr.986.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
10,531
52-wk High
kr.1,133.00
52-wk Low
kr.839.00

Latest Key Developments (Source: Significant Developments)

Successful phase III trial for Alk's tree allergy Slit-Tablet
Thursday, 14 Sep 2017 07:15am EDT 

Sept 14 (Reuters) - Alk-abello A/S ::Successful phase III trial for Alk's tree allergy slit-tablet.Alk-Abello A/S - ‍results of trial were highly statistically significant​.Alk-Abello - trial showed that treatment was well-tolerated by patients, with no new or unexpected adverse events reported.Alk-Abello - trial met its primary efficacy endpoint​.  Full Article

ALK to accelerate launches of Odactra in U.S.
Monday, 21 Aug 2017 12:59pm EDT 

Aug 21 (Reuters) - Alk-Abello A/S ::Says ‍FDA transferred U.S. product licences for slit-tablet portfolio to ALK.Says ‍ALK plans to expand pivotal phase III clinical trial on allergic asthma to include U.S. patients based on discussions with FDA​.Says FY guidance for operating profit (EBITDA) revised due to accelerated investments to support earlier launches of HDM-SLIT tablet in USA,CANADA​.Says ‍will bring forward North American launches of house dust mite SLIT-tablet from mid-2018 to Q4 2017​.Says ‍FY EBITDA is now expected to be approximately DKK 225-250 million​.Says ‍full-year revenue is still projected at DKK 2.8-3.0 billion​.Says ‍full year free cash flow is now expected at approximately minus DKK 700 million​.  Full Article

ALK-Abello Q2 EBIT loss at DKK 28 mln, higher than expected
Wednesday, 16 Aug 2017 01:45am EDT 

Aug 16 (Reuters) - ALK-ABELLO A/S :Q2 TOTAL REVENUE DKK ‍691​ MILLION (REUTERS POLL DKK 695 MILLION).‍FINANCIAL GUIDANCE FOR FULL-YEAR REVENUE AND OPERATING PROFIT (EBITDA) IS UNCHANGED.​.‍IS CURRENTLY EVALUATING OPPORTUNITIES TO MOVE FORWARD LAUNCHES OF ACARIZAX FROM 2018 TO 2017​.Q2 EBIT LOSS DKK 28 MILLION (REUTERS POLL LOSS DKK 7.18 MILLION).Q2 NET LOSS DKK 1 MILLION (REUTERS POLL LOSS DKK 3.9 MILLION).  Full Article

Alk-Abello CFO Flemming Pedersen to leave company
Monday, 31 Jul 2017 04:11am EDT 

July 31 (Reuters) - ALK-ABELLO A/S ::MANAGEMENT CHANGE AT ALK.FLEMMING PEDERSEN, CFO AND MEMBER OF BOARD OF MANAGEMENT, HAS DECIDED TO RESIGN HIS POSITION AND LEAVE ALK TO JOIN A PRIVATELY OWNED DANISH COMPANY IN ANOTHER INDUSTRY.FLEMMING PEDERSEN WILL LEAVE ALK BY 31 JANUARY 2018 AT LATEST.A SEARCH FOR A NEW CFO WILL NOW BE INITIATED.  Full Article

ALK-Abello Q1 EBITDA DKK 140 million
Tuesday, 9 May 2017 01:49am EDT 

May 9 (Reuters) - ALK-ABELLO A/S :Q1 TOTAL REVENUE DKK 789 MILLION VERSUS DKK 848 MILLION YEAR AGO.Q1 EBITDA DKK 140 MILLION VERSUS DKK 277 MILLION YEAR AGO.FULL-YEAR REVENUE IS PROJECTED AT DKK 2.8-3.0 BILLION (2016: DKK 3.0 BILLION).2017 OPERATING PROFIT (EBITDA) IS EXPECTED TO RETURN TO 2015-LEVELS BEFORE PARTNER INCOME AT APPROXIMATELY DKK 300 MILLION (2016: DKK 642 MILLION).FULL-YEAR GUIDANCE IS UNCHANGED FROM 2016 ANNUAL REPORT.  Full Article

Alk-Abello says co's Acarizax has been approved in Canada
Thursday, 4 May 2017 03:07pm EDT 

May 4 (Reuters) - Alk-abello A/S : :Co's house dust mite sublingual allergy immunotherapy tablet, Acarizax has been approved in Canada.  Full Article

ALK-Abello: Torii submits paediatric registration application for house dust mite SLIT-tablet in Japan
Friday, 24 Mar 2017 03:00am EDT 

ALK-Abello A/S :ALK’s partner, Torii, submits paediatric registration application for the house dust mite SLIT-tablet in Japan.  Full Article

ALK-Abello: FDA approval for HDM sublingual allergy immunotherapy tablet
Thursday, 2 Mar 2017 01:01am EST 

ALK-Abello A/S : Said on Wednesday FDA approved Biologics License Application (BLA) for ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet (ACARIZAX in Europe) . Approval of the HDM SLIT-tablet is not expected to have an impact on ALK's 2017 financial outlook .CEO says "approval of the HDM SLIT-tablet marks the beginning of a new era for ALK in the USA as we now take full control of the SLIT-tablet portfolio and integrate it into our existing US business".  Full Article

ALK-Abello: FDA approval for HDM sublingual allergy immunotherapy tablet
Wednesday, 1 Mar 2017 06:38pm EST 

ALK-Abello A/S : Said on Wednesday FDA approved Biologics License Application (BLA) for ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet (ACARIZAX in Europe) . Approval of the HDM SLIT-tablet is not expected to have an impact on ALK's 2017 financial outlook .CEO says "approval of the HDM SLIT-tablet marks the beginning of a new era for ALK in the USA as we now take full control of the SLIT-tablet portfolio and integrate it into our existing US business".  Full Article

Alk submits registration application for ragweed SLIT-tablet in Europe
Thursday, 16 Feb 2017 02:27am EST 

Alk Abello A/S : Alk submits registration application for ragweed SLIT-tablet in Europe .The European regulatory review process is anticipated to take approximately 12 months so that, subject to approval, first market introductions could take place from late 2018.  Full Article

BRIEF-Alk-Abello acts on French injunction

* ALK-ABELLO A/S - FRENCH NATIONAL AGENCY FOR MEDICINES AND HEALTH PRODUCTS SAFETY ISSUED INJUNCTION AGAINST ALK